Back

Gender differences in transthyretin cardiac amyloidosis

13 May 2024 (12:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 5 Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Cristina Goena Vives

Donostia University Hospital, Donostia (Spain)

7 More presentations in this session

Presentation thumbnail
Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy
Doctor M. Maurer (New York, US)
Abstract Slides Video
Presentation thumbnail
T-Amylo score for the diagnosis of transthyretin cardiac amyloidosis in patients with acute heart failure.
Ms M. Diez (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis
Mrs E. Lointier (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Right ventricular to pulmonary artery uncoupling is an early predictor of poor outcome in wild-type transthyretin cardiac amyloidosis
Doctor G. Sinigiani (Padua, IT)
Abstract Slides Video
Presentation thumbnail
Impairment of right ventricular to pulmonary artery coupling is associated with worse survival in cardiac amyloidosis
Doctor A. Jakstaite (Hannover, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 5

The Event

Event poster

Heart Failure 2024

13 May 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Sex-based differences in phenotypic expression and prognosis of transthyretin cardiac amyloidosis associated with the Val122Ile variant
thumbnail
Congress Presentation
Wild-type transthyretin cardiac amyloidosis: sex differences in prevalence, phenotype, and prognosis
thumbnail
Congress Presentation
Sex-differences from referral to tafamidis treatment outcomes in real-world patients with wild-type transthyretin amyloid cardiomyopathy.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources